Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma.

Iacoboni, GloriaRejeski, KaiVillacampa, Guillermovan Doesum, Jaap AChiappella, AnnalisaBonifazi, FrancescaLopez-Corral, Luciavan Aalderen, MichielKwon, MiMartínez-Cibrian, NuriaBramanti, StefaniaReguera-Ortega, Juan LuisCamacho-Arteaga, LinaSchmidt, ChristianMarín-Niebla, AnaKersten, Marie JoséMartin Garcia-Sancho, AlejandroZinzani, Pier LuigiCorradini, Paolovan Meerten, TomSubklewe, MarionBarba, Pere2023-05-032023-05-032022http://hdl.handle.net/10668/20251enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/AdultAntineoplastic AgentsHumansImmunotherapy, AdoptiveLymphoma, Mantle-CellNeoplasm Recurrence, LocalPyrimidinesReceptors, Chimeric AntigenReal-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma.research article35271707open access10.1182/bloodadvances.20210069222473-9537PMC9631549https://ashpublications.org/bloodadvances/article-pdf/6/12/3606/1902623/advancesadv2021006922.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9631549/pdf